# Biological and Biophysical Characterization of Hybrid PLCL Nanofibers Incorporating Stem Cell-Derived Secretome

**Authors:** Tanya Stoyanova, Lora Topalova, Dencho Gugutkov, Regina Komsa-Penkova, Stanimir Kyurkchiev, Iren Bogeva-Tsolova, Dobromir Dimitrov, Svetla Todinova, George Altankov

PMC · DOI: 10.3390/polym18040528 · 2026-02-21

## TL;DR

This study creates hybrid nanofiber scaffolds using PLCL and stem cell secretions to improve tissue regeneration by influencing cell behavior.

## Contribution

The novel contribution is the fabrication of aligned and random PLCL nanofibers incorporating stem cell-derived secretome to guide cell behavior.

## Key findings

- Aligned nanofibers led to smaller cell spreading and faster proliferation compared to random fibers.
- Aligned nanofibers promoted faster cell migration than random fibers and control substrates.

## Abstract

The design of multifunctional biomaterials that offer both structural support and biochemical cues is essential for enhancing tissue regeneration. In this study, hybrid nanofibrous scaffolds composed of poly(L-lactide-co-ε-caprolactone) (PLCL) and bioactive factors secreted by Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) were fabricated via co-electrospinning. Nanofibers were produced in aligned and random configurations following an optimized protocol developed at the Institute for Bioengineering of Catalonia (IBEC). Their morphology and topography were characterized by light microscopy, scanning electron microscopy (SEM), and atomic force microscopy (AFM), and fiber orientation was quantified via Fast Fourier Transform (FFT) analysis. The scaffolds showed fiber diameters of 542.9 ± 62.3 nm, with aligned fibers predominantly oriented within 20° of the principal axis. Human AD-MSCs were used to assess biocompatibility and cell–material interactions. Aligned and random nanofiber architectures elicited distinct cellular responses. AD-MSCs on aligned fibers exhibited smaller spreading areas (~320 μm2) vs. on random nanofibers (~500 μm2) and substantially higher proliferation, resulting in a shorter cell-doubling time (~25 h) than those on random nanofibers (~130 h) or control substrates (~70 h). In addition, aligned nanofibers promoted markedly faster migration, reaching rates of ~5000 μm2/h surface coverage, compared with random nanofibers (~770 μm2/h) and controls (~1800 μm2/h). Together, the results show that nanofiber alignment and biochemical functionalization jointly influence MSC behavior and improve regeneration, highlighting the potential of these PLCL-based hybrid secretome/PLCL nanofibers for advanced wound healing.

## Full-text entities

- **Genes:** VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, PIEZO1 (piezo type mechanosensitive ion channel component 1 (Er blood group)) [NCBI Gene 9780] {aka DHS, ER, FAM38A, LMPH3, LMPHM6, Mib}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, VCL (vinculin) [NCBI Gene 7414] {aka CMD1W, CMH15, HEL114, MV, MVCL, VINC}, CAMP (cathelicidin antimicrobial peptide) [NCBI Gene 820] {aka CAP-18, CAP18, CRAMP, FALL-39, FALL39, HSD26}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}
- **Diseases:** AD (MESH:D000544), injury to (MESH:D014947), inflammation (MESH:D007249), burns (MESH:D002056), venous leg ulcers (MESH:D014647), cytotoxicity (MESH:D064420), infection (MESH:D007239), diabetic ulcers (MESH:D017719), pressure injuries (MESH:D003668)
- **Chemicals:** ester (MESH:D004952), Triton X-100 (MESH:D017830), polymer (MESH:D011108), EDTA (MESH:D004492), caprolactone (MESH:C121056), F12 (MESH:C007782), chitosan (MESH:D048271), alginate (MESH:D000464), oxygen (MESH:D010100), Calcein AM (MESH:C085925), carbonate (MESH:D002254), HFIP (MESH:C001337), ethanol (MESH:D000431), FITC-phalloidin (MESH:C037191), amide (MESH:D000577), Hoechst 33258 (MESH:D006690), NaN3 (MESH:D019810), PCL (MESH:C016240), bicarbonate (MESH:D001639), propidium iodide (MESH:D011419), DMEM/ (-), polyurethane (MESH:D011140), PLA (MESH:C033616), paraformaldehyde (MESH:C003043), CO2 (MESH:D002245), lactide (MESH:C091880)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** WJ-MSC — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_B5SZ), WJ — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_W352), AD — Homo sapiens (Human), Lung small cell carcinoma, Cancer cell line (CVCL_0C05)

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943895/full.md

---
Source: https://tomesphere.com/paper/PMC12943895